Rebecca Taub

Company: Madrigal Pharmaceuticals

Job title: Chief Executive Officer

Seminars:

Development and Approval of Resmetirom for Treatment of Patients with MASH with Moderate to Advanced Liver Fibrosis 8:30 am

Understanding the development of Resmetirom based on serial liver biopsy testing to provide unambiguous histopathological evidence and rigorously assess fibrosis regression and MASH resolution to accelerate FDA approval Diagnosing and monitoring patients using non-invasive tests to stratify patients and monitor treatment response, to differentiate between cirrhotic from non-cirrhotic MASH, empowering clinicians to identify high-risk patients…Read more

day: Conference Day Two